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ABSTRACT
A growing amount of evidence indicates that autophagy plays a pivotal role in a plethora of human
pathological conditions. We have recently broadened the list of the so-called autophagy-related diseases,
describing the involvement of defective autophagy in the pathogenesis of cerebral cavernous
malformations. KEYWORDS
autophagy; CCM;
endothelial-to-mesenchymal
transition (EndMt); MTOR;
pharmacological therapy;
ROS
Cerebral cavernous malformations (CCMs; OMIM: 116860) consist
of conglomerations of sinusoidal capillaries in the brain with
enlarged and irregular architecture. These abnormal vascular struc-
tures are characterized by a thin endothelium devoid of normal ves-
sel wall components, and may result in intracerebral hemorrhage
and consequent pathological conditions. CCMs may arise sporadi-
cally or can be inherited as an autosomal dominant condition with
incomplete penetrance and variable expressivity. Loss-of-function
mutations of 3 different genes are associated with CCMs: KRIT1/
CCM1 (KRIT1, ankyrin repeat containing), CCM2 (MGC4607) and
PDCD10/CCM3 (programmed cell death 10). Approximately 30%
of people with CCMs experience clinical symptoms, such as seizures,
strokes, headaches, and focal neurological deficits. To date, treatment
of CCM lesions is mainly limited to neurosurgery; however, this is
not always practicable, especially for multiple CCMs or CCMs
located in sensitive areas of the brain. Therefore, novel pharmacolog-
ical approaches are required for preventing and treating this disease,
which should derive from a comprehensive understanding ofmolec-
ularmechanisms underlying CCMpathogenesis.
Over the past few years, several molecular pathways have been
associated with the genesis and progression of CCM lesions, includ-
ing but not limited to the RHO-ROCK, TGFB/TGF-b/BMP,
CTNNB1/b-catenin andNOTCHpathways, aswell as distinct redox
molecular routes modulated by reactive oxygen species (ROS). In
our study, we showed that downregulation of the KRIT1 gene indu-
ces defects in autophagic degradation, evidenced by increased levels
of both SQSTM1/p62 and MAP1LC3B proteins. Furthermore, we
observed accumulation of aggresome-like structures, as well as
increased amounts of SQSTM1-positive bodies in detergent-insolu-
ble fraction, reflecting the inefficiency of protein aggregate clearance
by the autophagic machinery. These findings have been obtained
both in multiple KRIT1-silenced endothelial cell lines and KRIT1-
knockout (KO) fibroblasts, suggesting that insufficient autophagy
occurred in a cell-autonomousmanner.
But what about the molecular mechanisms underpinning
KRIT1-dependent autophagy dysregulation? When analyzing the
appearance of KRIT1 KO cells, we observed an increase in size
and cell proliferation rate, 2 typical traits that can be connected to
MTOR (mechanistic target of rapamycin [serine/threonine
kinase]) activity. Indeed, KRIT1-depleted cells display hyperactiva-
tion of the MTOR pathway, with consequent reduced activity of
ULK1, one of the major targets of MTOR-dependent autophagy
regulation. Both Torin1 and rapamycin, 2 major MTOR inhibi-
tors, reestablish, at least in part, autophagy in KO cells, whereas
treatment with xestospongin B, an MTOR-independent pro-auto-
phagic stimulus, fails to restore the correct autophagic flux. Alto-
gether, these results demonstrate that the defective autophagy
observed upon KRIT1 loss is mainly due to MTOR activity.
The 3 proteins implicated in this disease may interact to form
the "CCM complex," which is involved in the maintenance of vas-
cular homeostasis. Moreover, mutations in any of the 3 CCM
genes lead to the onset of similar pathological signatures, suggest-
ing that the 3 CCM proteins share a common mechanism of
action or that the physiological activity of the complex is strictly
dependent on the correct function of its components. Thus, we
investigated if downregulation of CCM2 and PDCD10 expression
would have the same impact on the autophagic process. Both
CCM2-silenced and PDCD10-deficient endothelial cells exhibit
SQSTM1 andMAP1LC3B accumulation due toMTOR upregula-
tion. Importantly, analysis of retinas derived from an endothelial-
specific Pdcd10 knockout mouse model, which presents malfor-
mations at the periphery of retinal vascular plexus, display
SQSTM1 clusters in endothelial cells forming the vascular lesions.
Similar results have been obtained in surgical samples of human
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CCM lesions. Further studies are needed to identify themolecular
mechanism governing MTOR activation upon malfunctioning of
the CCM complex.
Is insufficient autophagy only a phenomenon that occurs
during CCMs or could it regulate other pathological aspects
that contribute to CCM progression? To address this relevant
question, we explored the correlation between autophagy and 2
major pathological signatures of the disease, such as endothe-
lial-to-mesenchymal transition (EndMt) and ROS production.
Treatment with MTOR inhibitors reduces expression of mesen-
chymal markers and augments the amounts of endothelial
markers, as well as restores cell migration to physiological lev-
els. In addition, pharmacological inhibition of MTOR also
decreases mitochondrial ROS production in KRIT1-KO cells.
Importantly, administration of antioxidants, such as N-acetyl
cysteine, reduces intracellular ROS levels but is unable to reacti-
vate autophagy or minimize the upregulated MTOR signaling
pathway occurring upon KRIT1 depletion. Moreover, ATG7
silencing in endothelial cells induces a mesenchymal switch,
evidenced by slow formation of capillary-like structures,
increased migratory capacity, and gain of specific biomarkers.
Thus, the MTOR-dependent inhibition of autophagy is closely
related to both EndMt and ROS accumulation, suggesting a
causative link.
Could defective autophagy be considered one of the main
routes leading to irregular endothelial growth and thus a prom-
ising target for a therapeutic approach? Recent findings demon-
strate that endothelial cell-specific knockdown of the ATG5
gene induces an increase in structural abnormalities of tumor
vasculature that are similar to those characterizing CCM ves-
sels, including the formation of large and leaky sinusoids. Most
importantly, different compounds proposed as noninvasive
drug treatment approaches for CCMs, including statins (e.g.,
Simvastatin), cholechalciferol (vitamin D3), and nonsteroidal
anti-inflammatory drugs (Sulindac sulfide and its analogs) have
been also described as pro-autophagic stimuli that function by
inhibiting the MTOR pathway (Fig. 1). Conversely, suppression
of autophagy might constitute a side effect that limits the effi-
cacy of some pharmacological therapies. This might be the case
for the nonselective b-adrenergic antagonist Propranolol,
which has been suggested as a potential candidate for treating
CCMs, but also as an inhibitor of autophagic flux and mild acti-
vator of MTOR, especially at high dosage. Overall, employment
of MTOR inhibitors, such as rapamycin, alone or in combina-
tion with adjuvant therapies, could represent a novel valuable
strategy for the treatment of CCM disease.
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Figure 1. Role of autophagy in cerebral cavernous malformations. CCMs are agglomerations of capillaries in the brain consisting of clustered, enlarged structures. The
figure illustrates some of the different molecular pathways that are altered upon loss-of-function mutation of CCM-associated genes. These include increased CTNNB1/
b-catenin and RHO-ROCK signaling, as well as suppression of the autophagic process through upregulation of MTOR. Therapeutic approaches depicted here, have been
also reported to trigger autophagy by MTOR inhibition. Please refer to the text for further explanation.
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